- Conditions
- Nausea, Vomiting, Satisfaction
- Interventions
- Acupressure Point P6 stimulator, Metoclopramide, Ondansetron
- Device · Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 222
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nausea, Vomiting
- Interventions
- aprepitant, Ondansetron
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Winston-Salem, North Carolina • Burlington, Vermont
- Conditions
- Cyclic Vomiting Syndrome
- Interventions
- Droperidol, Haloperidol, Ondansetron 8mg
- Drug
- Lead sponsor
- Corewell Health South
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Saint Joseph, Michigan
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- PONV
- Interventions
- Aprepitant Injection, Ondansetron (Zofran), Dexamethasone, Placebo
- Drug · Other
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Skokie, Illinois
- Conditions
- Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
- Interventions
- GW679769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 11
- States / cities
- San Francisco, California • Melbourne, Florida • West Palm Beach, Florida + 8 more
- Conditions
- Pain
- Interventions
- Macromastia
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Ketorolac, Standard of Care
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Nausea
- Interventions
- Bremelanotide, Zofran, Placebo
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 228 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Aprepitant, Ondansetron
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Nashville, Tennessee
- Conditions
- Gastroenteritis, Gastritis
- Interventions
- RHB-102, Placebo Oral Tablet
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 26
- States / cities
- Bakersfield, California • Sacramento, California • Sylmar, California + 19 more
- Conditions
- Hypotension, Pregnancy
- Interventions
- ondansetron, placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Nausea, Pain
- Interventions
- Prophylactic use of ibuprofen and ondansetron post misoprostol administration, Use of ibuprofen and ondansetron at symptom onset post misoprostol administration
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Alcohol Dependence
- Interventions
- naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Obsessive-Compulsive Disorder, Tic Disorders, Tourette Syndrome
- Interventions
- Ondansetron, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- BEKINDA, Placebo
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more
- Conditions
- Healthy
- Interventions
- Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Solid Tumors
- Interventions
- Wee-1 kinase inhibitor AZD1775
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- erlotinib hydrochloride, pemetrexed disodium, vinflunine
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Multiple Myeloma, Autologous Stem Cell Transplantation
- Interventions
- Olanzapine
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Postoperative Nausea and Vomiting (PONV), Nausea
- Interventions
- Aprepitant, Ondansetron, Promethazine, Dexamethasone
- Drug
- Lead sponsor
- Sergio Bergese
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Melanoma
- Interventions
- Cyclophosphamide
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Resected Pancreatic Adenocarcinoma
- Interventions
- mFOLFIRINOX, Proton beam radiation
- Drug · Radiation
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia